Insulin concentration modulates hepatic lipid accumulation in mice in part via transcriptional regulation of fatty acid transport proteins

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Softic, Samir ^a,b   Kirby, Michelle ^a   Berger, Nicholas G ^a   Shroyer, Noah F ^a   Woods, Stephen C ^c   Kohli, Rohit ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; FATTY ACID TRANSPORTER; FATTY ACID TRANSPORTER 2; FATTY ACID TRANSPORTER 5; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LIPID; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET RESTRICTION; ENZYME INHIBITION; FATTY LIVER; GENE SILENCING; HYPERINSULINEMIA; HYPOINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESPONSE; LIPID LIVER LEVEL; LIPID STORAGE; LIPOGENESIS; LIVER CELL; MALE; MOUSE; NONHUMAN; OBESITY; PATHOGENESIS; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; UPREGULATION;

ALANINE TRANSAMINASE; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FATTY ACID TRANSPORT PROTEINS; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; INSULIN; LIVER; MALE; MICE; TRIGLYCERIDES;

EID: 84862680029     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038952     Document Type: Article

References (50)

1. Angulo P, (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231.
2. Leeds JS, Forman EM, Morley S, Scott AR, Tesfaye S, et al. (2009) Abnormal liver function tests in patients with Type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies. Diabet Med 26: 1235-1241.
3. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, et al. (2010) Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 53: 713-718.
4. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, et al. (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103: 1489-1498.
5. Guan HP, Goldstein JL, Brown MS, Liang G, (2009) Accelerated fatty acid oxidation in muscle averts fasting-induced hepatic steatosis in SJL/J mice. J Biol Chem 284: 24644-24652.
6. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, et al. (2001) Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 15: 2099-2111.
7. Previs SF, Withers DJ, Ren JM, White MF, Shulman GI, (2000) Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem 275: 38990-38994.
8. Ruiz-Alcaraz AJ, Liu HK, Cuthbertson DJ, McManus EJ, Akhtar S, et al. (2005) A novel regulation of IRS1 (insulin receptor substrate-1) expression following short term insulin administration. Biochem J 392: 345-352.
9. Kubota N, Kubota T, Itoh S, Kumagai H, Kozono H, et al. (2008) Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metab 8: 49-64.
10. Canettieri G, Koo SH, Berdeaux R, Heredia J, Hedrick S, et al. (2005) Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling. Cell Metab 2: 331-338.
11. Ide T, Shimano H, Yahagi N, Matsuzaka T, Nakakuki M, et al. (2004) SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol 6: 351-357.
12. Haeusler RA, Accili D, (2008) The double life of Irs. Cell Metab 8: 7-9.
13. Masternak MM, Al-Regaiey KA, Del Rosario Lim MM, Jimenez-Ortega V, Panici JA, et al. (2005) Effects of caloric restriction on insulin pathway gene expression in the skeletal muscle and liver of normal and long-lived GHR-KO mice. Exp Gerontol 40: 679-684.
14. DiRusso CC, Li H, Darwis D, Watkins PA, Berger J, et al. (2005) Comparative biochemical studies of the murine fatty acid transport proteins (FATP) expressed in yeast. J Biol Chem 280: 16829-16837.
15. Cazanave SC, Gores GJ, (2010) Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol 5: 71-85.
16. Milger K, Herrmann T, Becker C, Gotthardt D, Zickwolf J, et al. (2006) Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4. J Cell Sci 119: 4678-4688.
17. Watkins PA, (2008) Very-long-chain acyl-CoA synthetases. J Biol Chem 283: 1773-1777.
18. Stahl A, Evans JG, Pattel S, Hirsch D, Lodish HF, (2002) Insulin causes fatty acid transport protein translocation and enhanced fatty acid uptake in adipocytes. Dev Cell 2: 477-488.
19. Hirsch D, Stahl A, Lodish HF, (1998) A family of fatty acid transporters conserved from mycobacterium to man. Proc Natl Acad Sci U S A 95: 8625-8629.
20. Sandoval A, Fraisl P, Arias-Barrau E, Dirusso CC, Singer D, et al. (2008) Fatty acid transport and activation and the expression patterns of genes involved in fatty acid trafficking. Arch Biochem Biophys 477: 363-371.
21. Falcon A, Doege H, Fluitt A, Tsang B, Watson N, et al. (2010) FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. Am J Physiol Endocrinol Metab 299: E384-393.
22. Doege H, Baillie RA, Ortegon AM, Tsang B, Wu Q, et al. (2006) Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology 130: 1245-1258.
23. Hubbard B, Doege H, Punreddy S, Wu H, Huang X, et al. (2006) Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology 130: 1259-1269.
24. Doege H, Grimm D, Falcon A, Tsang B, Storm TA, et al. (2008) Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J Biol Chem 283: 22186-22192.
25. Bechmann LP, Gieseler RK, Sowa JP, Kahraman A, Erhard J, et al. (2010) Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int 30: 850-859.
26. Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, et al. (2009) Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res 39: 366-373.
27. Auinger A, Valenti L, Pfeuffer M, Helwig U, Herrmann J, et al. (2010) A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis. Horm Metab Res 42: 854-859.
28. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, et al. (2010) High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52: 934-944.
29. Metcalfe LD, (1960) Gas chromatography of unesterified fatty acids using polyester columns treated with phosphoric acid. Nature 188: 142-143.
30. Jandacek RJ, Heubi JE, Tso P, (2004) A novel, noninvasive method for the measurement of intestinal fat absorption. Gastroenterology 127: 139-144.
31. Kohli R, Pan X, Malladi P, Wainwright MS, Whitington PF, (2007) Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. J Biol Chem 282: 21327-21336.
32. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM, (2004) Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol 41: 592-598.
33. Kusunoki M, Tsutsumi K, Inoue Y, Hara T, Miyata T, et al. (2004) Lipoprotein lipase activator NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin-induced diabetic rats. Metabolism 53: 260-263.
34. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, et al. (2004) Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40: 185-194.
35. Cherrington AD, (1999) Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48: 1198-1214.
36. Schaffer JE, Lodish HF, (1994) Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell 79: 427-436.
37. Heinzer AK, Watkins PA, Lu JF, Kemp S, Moser AB, et al. (2003) A very long-chain acyl-CoA synthetase-deficient mouse and its relevance to X-linked adrenoleukodystrophy. Hum Mol Genet 12: 1145-1154.
38. Hui TY, Frohnert BI, Smith AJ, Schaffer JE, Bernlohr DA, (1998) Characterization of the murine fatty acid transport protein gene and its insulin response sequence. J Biol Chem 273: 27420-27429.
39. Kerouz NJ, Horsch D, Pons S, Kahn CR, (1997) Differential regulation of insulin receptor substrates-1 and-2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J Clin Invest 100: 3164-3172.
40. Guo S, Copps KD, Dong X, Park S, Cheng Z, et al. (2009) The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 29: 5070-5083.
41. Taniguchi CM, Ueki K, Kahn R, (2005) Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 115: 718-727.
42. Rojas FA, Hirata AE, Saad MJ, (2001) Regulation of IRS-2 tyrosine phosphorylation in fasting and diabetes. Mol Cell Endocrinol 183: 63-69.
43. Simmgen M, Knauf C, Lopez M, Choudhury AI, Charalambous M, et al. (2006) Liver-specific deletion of insulin receptor substrate 2 does not impair hepatic glucose and lipid metabolism in mice. Diabetologia 49: 552-561.
44. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, et al. (2000) Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6: 77-86.
45. White MF, (2003) Insulin signaling in health and disease. Science 302: 1710-1711.
46. Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, et al. (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51: 1584-1592.
47. Luiken JJ, Koonen DP, Willems J, Zorzano A, Becker C, et al. (2002) Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 51: 3113-3119.
48. Standaert ML, Kanoh Y, Sajan MP, Bandyopadhyay G, Farese RV, (2002) Cbl, IRS-1, and IRS-2 mediate effects of rosiglitazone on PI3K, PKC-lambda, and glucose transport in 3T3/L1 adipocytes. Endocrinology 143: 1705-1716.
49. Smith U, Gogg S, Johansson A, Olausson T, Rotter V, et al. (2001) Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J 15: 215-220.
50. Gunton JE, Delhanty PJ, Takahashi S, Baxter RC, (2003) Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 88: 1323-1332.